UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

The Use of Biomarkers in Human Pharmacology (Phase I) Studies

Annual review of pharmacology and toxicology, 2015-01, Vol.55 (1), p.55-74

2015

Volltextzugriff (PDF)

E.05.01 Innovative tools for ‘proof-of-pharmacological-concept’ studies

European neuropsychopharmacology, 2014-10, Vol.24, p.S150-S150

2014

Volltextzugriff (PDF)

PK and PD of a nicotinic anticholineric challenge with mecamylamine in comparison to scopolamine

Clinical therapeutics, 2015-08, Vol.37 (8), p.e10-e11

2015

Volltextzugriff (PDF)

Metoclopramide as pharmacological tool to assess vasopressinergic co-activation of the hypothalamus–pituitary–adrenal (HPA) axis: A study in healthy volunteers

European neuropsychopharmacology, 2010-12, Vol.20 (12), p.866-874

2010

Volltextzugriff (PDF)

P.1.c.053 The effect of olanzapine on a tetrahydrocannabinol-induced increase on the positive and negative syndrome scale

European neuropsychopharmacology, 2010, Vol.20, p.S265-S265

2010

Volltextzugriff (PDF)

P.3.06 Cannabis co-administration potentiates MDMA effects on temperature and heart rate

European neuropsychopharmacology, 2009, Vol.19, p.S67-S67

2009

Volltextzugriff (PDF)

P.2.a.026 Effects of metoclopramide on 5-HTP induced activation of the hypothalamus-pituitary-adrenal (HPA) axis

European neuropsychopharmacology, 2008, Vol.18, p.S307-S307

2008

Volltextzugriff (PDF)

P.1.c.037 Surinabant inhibits the effects of delta 9-tetrahydrocannabinol in a novel tetrahydrocannabinol-challenge test

European neuropsychopharmacology, 2008, Vol.18, p.S240-S241

2008

Volltextzugriff (PDF)

P.1.c.049 Alertness and electrocortical activity after (co-)administration of MDMA and THC in healthy volunteers

European neuropsychopharmacology, 2008, Vol.18, p.S247-S248

2008

Volltextzugriff (PDF)

P.1.c.023 Neuroendocrine effects and safety of intravenously administered desmopressin in healthy volunteers

European neuropsychopharmacology, 2008, Vol.18, p.S233-S233

2008

Volltextzugriff (PDF)

P.3.d.003 Study investigating R231857 effects on scopolamine-induced CNS impairment in healthy men

European neuropsychopharmacology, 2008, Vol.18, p.S449-S450

2008

Volltextzugriff (PDF)

P.2.03 Ecstasy and ethanol interaction effects on psychomotor function

European neuropsychopharmacology, 2007, Vol.17, p.S42-S42

2007

Volltextzugriff (PDF)

P.1.c.024 Tolerability of the 5-hydroxytryptophane challenge test with granisetron and domperidone

European neuropsychopharmacology, 2007, Vol.17, p.S255-S256

2007

Volltextzugriff (PDF)

MK-0873, a PDE4 inhibitor, does not influence the pharmacokinetics of theophylline in healthy male volunteers

Pulmonary pharmacology & therapeutics, 2008-01, Vol.21 (3), p.573-577

2008

Volltextzugriff (PDF)

Effect of intrapulmonary tetrahydrocannabinol administration in humans

Journal of psychopharmacology (Oxford), 2008-09, Vol.22 (7), p.707-716

2008

Volltextzugriff (PDF)

Modelling of the concentration—effect relationship of THC on central nervous system parameters and heart rate — insight into its mechanisms of action and a tool for clinical research and development of cannabinoids

Journal of psychopharmacology (Oxford), 2008-09, Vol.22 (7), p.717-726

2008

Volltextzugriff (PDF)

The effects of the glycine reuptake inhibitor R213129 on the central nervous system and on scopolamine-induced impairments in psychomotor and cognitive function in healthy subjects

Journal of psychopharmacology (Oxford), 2010-11, Vol.24 (11), p.1671-1679

2010

Volltextzugriff (PDF)

Pharmacodynamic and pharmacokinetic effects of TPA023, a GABAA α2,3 subtype-selective agonist, compared to lorazepam and placebo in healthy volunteers

Journal of psychopharmacology (Oxford), 2007-07, Vol.21 (4), p.374-383

2007

Volltextzugriff (PDF)

Pharmacodynamic and pharmacokinetic effects of MK-0343, a GABAA α2,3 subtype selective agonist, compared to lorazepam and placebo in healthy male volunteers

Journal of psychopharmacology (Oxford), 2008-01, Vol.22 (1), p.24-32

2008

Volltextzugriff (PDF)

Hypothalamic glutamate levels following serotonergic stimulation: A pilot study using 7-Tesla magnetic resonance spectroscopy in healthy volunteers

Progress in neuro-psychopharmacology & biological psychiatry, 2010-04, Vol.34 (3), p.486-491

2010

Volltextzugriff (PDF)

Cannabidiol in anxiety research – a translational integration of preclinical and clinical studies

Neuroscience Applied, 2022, Vol.1, p.100743, Article 100743

2022

Volltextzugriff (PDF)

Delta 9-tetrahydrocannabinol induces dopamine release in the human striatum

NeuroImage (Orlando, Fla.), 2008, Vol.41, p.T57-T57

2008

Volltextzugriff (PDF)

Pharmacodynamic and pharmacokinetic effects of MK-0343, a GABAA a2,3 subtype selective agonist, compared to lorazepam and placebo in healthy male volunteers

Journal of psychopharmacology (Oxford), 2008-01, Vol.22 (1), p.24

2008

Volltextzugriff (PDF)

Pharmacodynamic and pharmacokinetic effects of MK-0343, a GABA A α 2,3 subtype selective agonist, compared to lorazepam and placebo in healthy male volunteers

Journal of psychopharmacology (Oxford), 2008-01, Vol.22 (1), p.24-32

2008

Volltextzugriff (PDF)

Pharmacodynamic and pharmacokinetic effects of TPA023, a GAB[A.sub.A] [α.sub.2,3] subtype-selective agonist, compared to lorazepam and placebo in healthy volunteers

Journal of psychopharmacology (Oxford), 2007-07, Vol.21 (4), p.374

2007

Volltextzugriff (PDF)

1 – 25 von 37

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(36)
Mit Volltextzugriff
(36)

Publikationsform

Artikel
(37)

Sprache

Englisch
(37)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

The Use of Biomarkers in Human Pharmacology (Phase I) Studies

E.05.01 Innovative tools for ‘proof-of-pharmacological-concept’ studies

PK and PD of a nicotinic anticholineric challenge with mecamylamine in comparison to scopolamine

Metoclopramide as pharmacological tool to assess vasopressinergic co-activation of the hypothalamus–pituitary–adrenal (HPA) axis: A study in healthy volunteers

P.1.c.053 The effect of olanzapine on a tetrahydrocannabinol-induced increase on the positive and negative syndrome scale

P.3.06 Cannabis co-administration potentiates MDMA effects on temperature and heart rate

P.2.a.026 Effects of metoclopramide on 5-HTP induced activation of the hypothalamus-pituitary-adrenal (HPA) axis

P.1.c.037 Surinabant inhibits the effects of delta 9-tetrahydrocannabinol in a novel tetrahydrocannabinol-challenge test

P.1.c.049 Alertness and electrocortical activity after (co-)administration of MDMA and THC in healthy volunteers

P.1.c.023 Neuroendocrine effects and safety of intravenously administered desmopressin in healthy volunteers

P.3.d.003 Study investigating R231857 effects on scopolamine-induced CNS impairment in healthy men

P.2.03 Ecstasy and ethanol interaction effects on psychomotor function

P.1.c.024 Tolerability of the 5-hydroxytryptophane challenge test with granisetron and domperidone

MK-0873, a PDE4 inhibitor, does not influence the pharmacokinetics of theophylline in healthy male volunteers

Effect of intrapulmonary tetrahydrocannabinol administration in humans

Modelling of the concentration—effect relationship of THC on central nervous system parameters and heart rate — insight into its mechanisms of action and a tool for clinical research and development of cannabinoids

The effects of the glycine reuptake inhibitor R213129 on the central nervous system and on scopolamine-induced impairments in psychomotor and cognitive function in healthy subjects

Pharmacodynamic and pharmacokinetic effects of TPA023, a GABAA α2,3 subtype-selective agonist, compared to lorazepam and placebo in healthy volunteers

Pharmacodynamic and pharmacokinetic effects of MK-0343, a GABAA α2,3 subtype selective agonist, compared to lorazepam and placebo in healthy male volunteers

Hypothalamic glutamate levels following serotonergic stimulation: A pilot study using 7-Tesla magnetic resonance spectroscopy in healthy volunteers

Cannabidiol in anxiety research – a translational integration of preclinical and clinical studies

Delta 9-tetrahydrocannabinol induces dopamine release in the human striatum

Pharmacodynamic and pharmacokinetic effects of MK-0343, a GABAA a2,3 subtype selective agonist, compared to lorazepam and placebo in healthy male volunteers

Pharmacodynamic and pharmacokinetic effects of MK-0343, a GABA A α 2,3 subtype selective agonist, compared to lorazepam and placebo in healthy male volunteers

Pharmacodynamic and pharmacokinetic effects of TPA023, a GAB[A.sub.A] [α.sub.2,3] subtype-selective agonist, compared to lorazepam and placebo in healthy volunteers

Suchergebnisse filtern